{"id":23878,"date":"2025-12-11T08:26:03","date_gmt":"2025-12-11T12:26:03","guid":{"rendered":"https:\/\/red94.net\/news\/lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-loss-in-phase-3-trial\/"},"modified":"2025-12-11T08:26:16","modified_gmt":"2025-12-11T12:26:16","slug":"45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l","status":"publish","type":"post","link":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/","title":{"rendered":"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial"},"content":{"rendered":"

LLY stock<\/b> soared nearly 3%<\/b> today after Eli Lilly<\/b> announced that retatrutide<\/b> delivered stunning 28.7% weight loss<\/b> in a Phase 3 trial. The next-generation obesity drug demonstrated unprecedented efficacy in the TRIUMPH-4<\/b> study. Market investors responded immediately to the breakthrough, driving the pharmaceutical giant’s stock higher.<\/p>\n

\n

\ud83d\udd25 Quick Facts<\/h3>\n
    \n
  • TRIUMPH-4 trial<\/b> showed 28.7% average weight loss<\/b> (71.2 lbs) in 68 weeks with highest dose<\/li>\n
  • LLY stock<\/b> climbed 3%<\/b> on December 11, 2025, following the announcement<\/li>\n
  • Pain relief<\/b>: Patients experienced up to 75.8% reduction<\/b> in knee pain scores<\/li>\n
  • Seven additional Phase 3 trials<\/b> expected to complete in 2026<\/b> for obesity and type 2 diabetes<\/li>\n<\/ul>\n<\/div>\n

    LLY Stock Responds to Retatrutide’s Game-Changing Trial Win<\/h2>\n

    Eli Lilly<\/b>‘s stock surge reflects market confidence in retatrutide<\/b>‘s commercial potential. The 3% jump<\/b> today positions LLY<\/b> as a leader in next-generation weight loss therapy. The drug’s performance exceeded expectations, with investors betting on continued momentum through 2026.<\/p>\n

    The TRIUMPH-4<\/b> trial included patients with both obesity and knee osteoarthritis. Results showed participants taking the 12 mg dose<\/b> lost an average of 71.2 pounds<\/b> over 68 weeks. This compares favorably to Zepbound<\/b> (tirzepatide), which achieved 20.2% weight loss<\/b> in earlier trials.<\/p>\n

    Retatrutide Delivers Triple-Hormone Action Without Precedent<\/h2>\n\n\n\n\n\n\n
    Clinical Metric<\/td>\nTRIUMPH-4 Results<\/td>\n<\/tr>\n
    Weight Loss (12 mg dose)<\/td>\n28.7% average (71.2 lbs)<\/td>\n<\/tr>\n
    Trial Duration<\/td>\n68 weeks<\/td>\n<\/tr>\n
    Knee Pain Reduction<\/td>\nUp to 75.8% pain relief<\/td>\n<\/tr>\n
    Complete Pain Relief<\/td>\n12-14% of patients pain-free<\/td>\n<\/tr>\n<\/table>\n

    Retatrutide<\/b> functions as a triple-hormone agonist<\/b>, activating three key receptors simultaneously. This mechanism differs from Zepbound<\/b>, which is a dual agonist. The triple action<\/b> targets GLP-1<\/b>, GIP<\/b>, and glucagon receptors<\/b>, maximizing weight loss potential.<\/p>\n

    Analysts believe retatrutide’s efficacy addresses the obesity treatment<\/b> market gap between current therapies and ideal outcomes. The drug’s ability to reduce both weight and joint pain simultaneously opens new commercial pathways for Eli Lilly<\/b>.<\/p>\n

    Wall Street Exceeded Expectations in Latest TRIUMPH-4 Results<\/h2>\n

    Market expectations<\/b> predicted approximately 20-23% weight loss<\/b> for retatrutide<\/b> Phase 3 trials. The actual 28.7% result<\/b> significantly surpassed forecasts. Bloomberg<\/b> reports that Wall Street<\/b> expected at least 50% pain reduction<\/b> for knee osteoarthritis\u2014TRIUMPH-4<\/b> achieved 75.8% pain relief<\/b>.<\/p>\n

    This performance validates Eli Lilly<\/b>‘s strategy to position retatrutide<\/b> as a breakthrough therapy. The company previously demonstrated 24.2% weight loss<\/b> in mid-stage trials. Today’s Phase 3<\/b> announcement represents meaningful progression toward regulatory approval.<\/p>\n

    \n“Retatrutide appears to be the most weight loss seen so far in a late-stage trial.”\n<\/p><\/blockquote>\n

    \u2014 Simon Campbell<\/b>, STAT News Analysis<\/p>\n

    Pipeline Expansion: Seven Trials Expected to Report During 2026<\/h2>\n

    Eli Lilly<\/b> disclosed that seven additional Phase 3 trials<\/b> for retatrutide<\/b> are expected to complete in 2026<\/b>. These studies evaluate the drug in obesity<\/b>, type 2 diabetes<\/b>, and other chronic conditions. The company’s aggressive timeline suggests potential FDA approval<\/b> could arrive sooner than previously anticipated.<\/p>\n

    Upcoming trials include evaluations for cardiovascular outcomes<\/b>, chronic kidney disease<\/b>, and metabolic dysfunction-associated fatty liver disease (MAFLD)<\/b>. Each successful readout strengthens LLY<\/b>‘s competitive position against Novo Nordisk<\/b> and emerging competitors.<\/p>\n

    Could Retatrutide Reshape the $100+ Billion Weight Loss Market?<\/h2>\n

    Retatrutide<\/b>‘s superior efficacy compared to Zepbound<\/b> and Wegovy<\/b> positions the drug to capture significant market share. Analysts project the global obesity treatment market could reach $100+ billion<\/b> by 2030. LLY<\/b>‘s early-first-mover advantage with retatrutide<\/b> offers substantial growth opportunity.<\/p>\n

    The December 11<\/b> announcement energized institutional investors who recognize retatrutide<\/b>‘s blockbuster potential. LLY<\/b> stock has climbed 27%<\/b> over the past month, reflecting broadening confidence in the company’s obesity pipeline. Today’s 3% gain<\/b> represents continued momentum from TRIUMPH-4<\/b> validation.<\/p>\n

    Sources<\/h3>\n
      \n
    • Reuters<\/b> – Eli Lilly weight loss drug trial results December 2025<\/li>\n
    • CNBC<\/b> – Retatrutide Phase 3 late-stage study announcement<\/li>\n
    • Financial Times<\/b> – Eli Lilly obesity drug breakthrough weight loss data<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":23,"featured_media":23877,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"schema_org_data":"{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Person\",\"name\":\"Simon Campbell\",\"sameAs\":[\"https:\/\/www.themoviedb.org\/person\/5331403\"]}]}","_extracted_celebrities":null,"_extracted_movies":"","_extracted_places":"","_extracted_videos":"","_last_enrichment_date":"2025-12-11 08:26:25","footnotes":""},"categories":[391],"tags":[],"class_list":["post-23878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-finance","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"yoast_head":"\nLLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial\" \/>\n<meta property=\"og:description\" content=\"…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/\" \/>\n<meta property=\"og:site_name\" content=\"Red94\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T12:26:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T12:26:16+00:00\" \/>\n<meta name=\"author\" content=\"Patrick Graham\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patrick Graham\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/\"},\"author\":{\"name\":\"Patrick Graham\",\"@id\":\"https:\/\/red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9\"},\"headline\":\"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial\",\"datePublished\":\"2025-12-11T12:26:03+00:00\",\"dateModified\":\"2025-12-11T12:26:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/\"},\"wordCount\":583,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/red94.net\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/12\/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png\",\"articleSection\":[\"Business & Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/\",\"url\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/\",\"name\":\"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial\",\"isPartOf\":{\"@id\":\"https:\/\/red94.net\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/12\/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png\",\"datePublished\":\"2025-12-11T12:26:03+00:00\",\"dateModified\":\"2025-12-11T12:26:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#primaryimage\",\"url\":\"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/12\/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png\",\"contentUrl\":\"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/12\/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png\",\"width\":1360,\"height\":768,\"caption\":\"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/red94.net\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entertainment\",\"item\":\"https:\/\/red94.net\/news\/entertainment\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/red94.net\/news\/#website\",\"url\":\"https:\/\/red94.net\/news\/\",\"name\":\"Red94\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/red94.net\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/red94.net\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/red94.net\/news\/#organization\",\"name\":\"Red94\",\"url\":\"https:\/\/red94.net\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/red94.net\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png\",\"contentUrl\":\"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png\",\"width\":289,\"height\":90,\"caption\":\"Red94\"},\"image\":{\"@id\":\"https:\/\/red94.net\/news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9\",\"name\":\"Patrick Graham\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/red94.net\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg\",\"contentUrl\":\"https:\/\/red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg\",\"caption\":\"Patrick Graham\"},\"description\":\"Patrick Graham is a business and finance journalist translating Wall Street's complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world's biggest moves.\",\"url\":\"https:\/\/red94.net\/news\/author\/patrick-graham\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/","og_locale":"en_US","og_type":"article","og_title":"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial","og_description":"…","og_url":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/","og_site_name":"Red94","article_published_time":"2025-12-11T12:26:03+00:00","article_modified_time":"2025-12-11T12:26:16+00:00","author":"Patrick Graham","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Patrick Graham","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#article","isPartOf":{"@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/"},"author":{"name":"Patrick Graham","@id":"https:\/\/red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9"},"headline":"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial","datePublished":"2025-12-11T12:26:03+00:00","dateModified":"2025-12-11T12:26:16+00:00","mainEntityOfPage":{"@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/"},"wordCount":583,"commentCount":0,"publisher":{"@id":"https:\/\/red94.net\/news\/#organization"},"image":{"@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#primaryimage"},"thumbnailUrl":"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/12\/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png","articleSection":["Business & Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/","url":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/","name":"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial","isPartOf":{"@id":"https:\/\/red94.net\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#primaryimage"},"image":{"@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#primaryimage"},"thumbnailUrl":"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/12\/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png","datePublished":"2025-12-11T12:26:03+00:00","dateModified":"2025-12-11T12:26:16+00:00","breadcrumb":{"@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#primaryimage","url":"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/12\/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png","contentUrl":"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/12\/74071-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l.jpg.png","width":1360,"height":768,"caption":"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial"},{"@type":"BreadcrumbList","@id":"https:\/\/red94.net\/news\/45993-lly-stock-soars-nearly-3-today-after-retatrutide-delivers-stunning-28-7-weight-l\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/red94.net\/news\/"},{"@type":"ListItem","position":2,"name":"Entertainment","item":"https:\/\/red94.net\/news\/entertainment\/"},{"@type":"ListItem","position":3,"name":"LLY stock soars nearly 3% today after retatrutide delivers stunning 28.7% weight loss in Phase 3 trial"}]},{"@type":"WebSite","@id":"https:\/\/red94.net\/news\/#website","url":"https:\/\/red94.net\/news\/","name":"Red94","description":"","publisher":{"@id":"https:\/\/red94.net\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/red94.net\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/red94.net\/news\/#organization","name":"Red94","url":"https:\/\/red94.net\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/red94.net\/news\/#\/schema\/logo\/image\/","url":"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png","contentUrl":"https:\/\/red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png","width":289,"height":90,"caption":"Red94"},"image":{"@id":"https:\/\/red94.net\/news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9","name":"Patrick Graham","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/red94.net\/news\/#\/schema\/person\/image\/","url":"https:\/\/red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg","contentUrl":"https:\/\/red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg","caption":"Patrick Graham"},"description":"Patrick Graham is a business and finance journalist translating Wall Street's complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world's biggest moves.","url":"https:\/\/red94.net\/news\/author\/patrick-graham\/"}]}},"views":335,"_links":{"self":[{"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/posts\/23878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/comments?post=23878"}],"version-history":[{"count":0,"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/posts\/23878\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/media\/23877"}],"wp:attachment":[{"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/media?parent=23878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/categories?post=23878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/red94.net\/news\/wp-json\/wp\/v2\/tags?post=23878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}